Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors

被引:19
作者
Pi-Sunyer, F. Xavier [1 ]
机构
[1] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Div Endocrinol Diabet & Nutr, New York, NY 10025 USA
关键词
therapeutic lifestyle changes; formula diets; sibutramine; orlistat; phentermine;
D O I
10.1038/oby.2006.293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intervention in weight management should begin before the onset of the metabolic syndrome. Therapeutic lifestyle changes (e.g., diet and physical activity) comprise the cornerstone of care for overweight and obese patients. Behavior modification approaches are useful in facilitating adherence to specific dietary regimens. Pharmacotherapy is an option for patients with a BMI >30 kg/m(2) or for those with a BMI of 27 to 30 kg/m(2) and two or more risk factors, who have failed on diet and exercise alone. To date, the U.S. Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine.
引用
收藏
页码:135S / 142S
页数:8
相关论文
共 33 条
[1]   The role of low-fat diets in body weight control:: a meta-analysis of ad libitum dietary intervention studies [J].
Astrup, A ;
Grunwald, GK ;
Melanson, EL ;
Saris, WHM ;
Hill, JO .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (12) :1545-1552
[2]   Drug Treatment of Obesity [J].
Bray G.A. .
Reviews in Endocrine and Metabolic Disorders, 2001, 2 (4) :403-418
[3]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[4]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242
[5]   Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction - Final report of the Lyon Diet Heart Study [J].
de Lorgeril, M ;
Salen, P ;
Martin, JL ;
Monjaud, I ;
Delaye, J ;
Mamelle, N .
CIRCULATION, 1999, 99 (06) :779-785
[6]  
Ditschuneit HH, 1999, AM J CLIN NUTR, V69, P198
[7]   Orlistat in the long-term treatment of obesity in primary care settings [J].
Hauptman, J ;
Lucas, C ;
Boldrin, MN ;
Collins, H ;
Segal, KR .
ARCHIVES OF FAMILY MEDICINE, 2000, 9 (02) :160-167
[8]  
Higgins M, 1988, Acta Med Scand Suppl, V723, P23
[9]   Role of orlistat in the treatment of obese patients with type 2 diabetes - A 1-year randomized double-blind study [J].
Hollander, PA ;
Elbein, SC ;
Hirsch, IB ;
Kelley, D ;
McGill, J ;
Taylor, T ;
Weiss, SR ;
Crockett, SE ;
Kaplan, RA ;
Comstock, J ;
Lucas, CP ;
Lodewick, PA ;
Canovatchel, W ;
Chung, J ;
Hauptman, J .
DIABETES CARE, 1998, 21 (08) :1288-1294
[10]   Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women - A randomized trial [J].
Jakicic, JM ;
Winters, C ;
Lang, W ;
Wing, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (16) :1554-1560